Sara Fernández-Luis

Dr. Sara Fernández-Luis

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
MSMaria Queralt Salas
Maria Queralt Salas
ECEnric Cascos
Enric Cascos
ALAlberto López-García
Alberto López-García
EPEstefanía Pérez
Estefanía Pérez
MBMónica Baile-González
Mónica Baile-González
MCManuel Jurado Chacón
Manuel Jurado Chacón
This multicenter study sponsored by the GETH-TC investigates the incidence and predictors of early (first 100 days) and late cardiac events (CEs; ECEs and LCEs, respectively) after allo-HCT in patients with acute myeloid leukemia (AML) treated with anthracyclines, focusing on exploring the impact of PTCY on cardiac complications and the impact of CEs on OS and NRM. A total of 1020 patients with AML were included. PTCY was given to 450 (44.1%) adults. Overall, 94 (9.2) patients experienced CEs, with arrythmias, pericardial complications, and heart failure the most prevalent. ECEs occurred in 49 (4.8%) patients within a median of 13 days after allo-HCT, whereas LCEs were diagnosed in 45 (4.4%) patients within a median of 3.6 years after transplant. Using PTCY increased the risk for ECEs in multivariate analysis (hazard ratio [HR], 2.86; P = .007) but did not significantly affect the risk for LCEs (HR, 1.06; P = .892). The impact of variables on outcomes revealed was investigated using multivariate regression analyses and revealed that the diagnosis of CEs decreased the likelihood of OS (HR, 1.66; P = .005) and increased the likelihood of NRM (HR, 2.88; P < .001). Furthermore, despite using PTCY increased ECEs risk, its administration was beneficial for OS (HR, 0.71; P = .026). In conclusion, although the incidence of CEs was relatively low, it significantly affected mortality. Standard doses of PTCY increased ECE risk but were associated with improved OS. Therefore, protocols for preventing cardiac complications among these patients are needed.

14 September 2024 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MSMaria Queralt Salas
Maria Queralt Salas
ECEnric Cascos
Enric Cascos
ALAlberto López-García
Alberto López-García
EPEstefanía Pérez-López
Estefanía Pérez-López
MBMónica Baile-González
Mónica Baile-González
MCManuel Jurado Chacón
Manuel Jurado Chacón

17 June 2025 in Transplantation
Verified
Journal Article
Closed access
SFSara Fernández-Luis
Sara Fernández-Luis
ABArancha Bermúdez
Arancha Bermúdez
LSLucrecia Yáñez San Segundo
Lucrecia Yáñez San Segundo
MGMónica Baile González
Mónica Baile González
SASara Rn Marcos Asensio
Sara Rn Marcos Asensio
ABAnna Sureda Balari
Anna Sureda Balari
Background. The number of elderly patients who could benefit from an allogeneic hematopoietic stem cell transplantation (allo-HSCT) is continuously increasing; however, the most appropriate way to select elderly candidates for this procedure is still a matter of debate. Methods. We report the clinical outcomes of a group of 529 patients aged 65 y and older who received a first allo-HSCT between 2011 and 2020 and were reported to the Grupo Español de Trasplante Hematopoyético y Terapia Celular database. Results. The median age was 67.2 y (range, 65–82) and 54 patients (10.2%) were 70 y and older. The 4-y cumulative incidence (CI) of nonrelapse mortality was 32.0% (95% confidence interval [CI], 28-36), CI of relapse was 29.1% (95% CI, 25-33), of overall survival was 43.4% (95% CI, 39-48), of progression-free survival was 38.9% (95% CI, 35-43), and of graft-versus-host disease (GvHD)-free, relapse-free survival was 23.7% (95% CI, 20-28). The 100-d CI of grades II–IV and III–IV acute GvHD was 34.7% (95% CI, 31-39) and 10.4% (95% CI, 8-13), respectively, and the 2-y CI of moderate-severe chronic GvHD was 21.0% (95% CI, 18-25). In the multivariate analysis, a hematopoietic cell transplantation-specific comorbidity index of ≥3 and a high/very high disease risk index were associated with worse overall survival; however, age did not influence the outcomes. Conclusions. Advanced age alone should not serve as an exclusion criterion for allo-HSCT, as the procedure can be both safe and effective in elderly patients with careful candidate selection and optimized transplant strategies. Export

12 August 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
CTCarles Tolosa‐Ridao
Carles Tolosa‐Ridao
MGMónica Baile González
Mónica Baile González
MGMarina Acera Gómez
Marina Acera Gómez
LFLaura Fox
Laura Fox
MAMaría del Mar Pérez Artigas
María del Mar Pérez Artigas
MSMaria Queralt Salas
Maria Queralt Salas

26 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ATArnau Torrent-Rodríguez
Arnau Torrent-Rodríguez
ECEnric Cascos
Enric Cascos
VGVictor Navarro Garcés
Victor Navarro Garcés
EPEstefanía Pérez-López
Estefanía Pérez-López
MBMónica Baile-González
Mónica Baile-González
MSMaria Queralt Salas
Maria Queralt Salas
Background: Post-transplant cyclophosphamide (PTCy) is a standard graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic cell transplantation (allo-HCT). While effective, concerns remain about cyclophosphamide-related cardiotoxicity, especially in patients with pre-existing cardiac morbidity, a population often underrepresented in clinical trials. Objectives: To assess the incidence and outcomes of early (ECE, ≤100 days) and late (LCE, >100 days) cardiac events in acute myeloid leukemia (AML) patients with and without baseline cardiac morbidity undergoing allo-HCT with PTCy. Study Design: Retrospective multicenter study by the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC) including 461 AML patients (62 with cardiac morbidity) transplanted between 2012 and 2022. Cardiac morbidity was defined by documented cardiac disease or left ventricular ejection fraction < 45%. Cumulative incidence, overall survival (OS), and non-relapse mortality (NRM) were analyzed using competing risks models and adjusted with propensity score matching (PSM) and inverse probability weighting (IPW). Results: Cardiac events occurred in 13.2% of patients: 11% vs. 7% ECE (p = 0.93) and 8% vs. 5.3% LCE (p = 0.85) in those with vs. without cardiac morbidity. Most ECEs were arrhythmias or heart failure. Adjusted analyses confirmed no significant differences in CE incidence, OS, or NRM between groups. Two-year OS was 69% vs. 70% (p = 0.50); NRM was 18% vs. 17% (p = 0.20). ECE was associated with higher mortality in both groups. Conclusions: PTCy is feasible in AML patients with pre-existing cardiac morbidity when combined with comprehensive cardiovascular evaluation and cardio-oncology follow-up, supporting its safe use in broader patient populations with appropriate cardiologic support.

10 October 2025 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CGClaudia González-Rico
Claudia González-Rico
Marta HernandezMarta Hernandez
Marta Hernandez
JRJorge Rodríguez-Grande
Jorge Rodríguez-Grande
SFSara Fernández-Luis
Sara Fernández-Luis
ARArancha Bermúdez Rodríguez
Arancha Bermúdez Rodríguez
MFMaría Carmen Fariñas
María Carmen Fariñas
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with significant alterations in gut microbiota (GM) composition, affecting transplant success. This study aimed to correlate these GM changes with post-transplant (post-HSCT) outcomes. A prospective multicentre cohort study was conducted between June 2017 and December 2021 in three Spanish hospitals. Stool samples from allo-HSCT recipients were collected before HSCT, and at 14-, 30-, 60-, and 100-days post-HSCT. Bacterial 16S rRNA gene sequences were characterized and microbial diversity assessed. Analysis of 409 samples from 95 patients revealed significant longitudinal GM shifts. Alpha diversity significantly decreased at days 14 (P < 0.001), 30 (P < 0.001), and 60 (P = 0.002) compared to baseline. A distinct shift in dominant taxonomic profiles was observed, notably a significant decrease in Blautia abundance (P < 0.001). Patients with acute gastrointestinal graft-versus-host disease (GI-GVHD) (P = 0.009), bacteraemia (P = 0.014), or death (P < 0.001) exhibited significantly lower Blautia levels. LEfSe analysis identified 22 differential taxa between deceased and surviving patients; the former showed higher abundance of potential pathogens such as Enterococcus_H (P = 0.026), Enterococcus_A (P = 0.019), and Staphylococcus (P = 0.009). Significant variations in the GM's taxonomic profiles and relative abundances post-HSCT, particularly the decrease in Blautia and the increase in certain pathogens, are associated with poorer clinical outcomes.